Febuxostat 80 mg is a potent, selective xanthine oxidase inhibitor formulated for advanced management of gout and chronic hyperuricemia. Gout develops when uric acid levels rise excessively and form sharp crystals inside the joints, leading to severe pain, swelling, and inflammation. Febuxostat works by inhibiting xanthine oxidase—the key enzyme responsible for uric acid production—helping reduce urate buildup, prevent flare-ups, and protect joints from long-term damage. UXOBUS-80 offers stronger uric acid–lowering action, making it suitable for patients requiring higher therapeutic control. Its consistent, once-daily formulation provides dependable serum urate management for long-term therapy.
Febuxostat (80 mg): A high-strength, non-purine xanthine oxidase inhibitor designed to significantly reduce uric acid formation and prevent recurrent gout attacks.
Enhanced Uric Acid Reduction: Provides stronger urate-lowering activity for patients needing robust control.
Selective XO Inhibition: Targets the main uric acid–producing pathway for reliable therapeutic efficacy.
Prevents Gout Progression: Helps reduce risks of tophi development, joint damage, and chronic inflammation.
Once-Daily Dosing: Convenient regimen supports long-term therapy and improved compliance.
Stable, Long-Term Use: Optimized formulation designed for sustained serum uric acid management.
Mild reactions may include headache, nausea, skin rash, joint discomfort, or slight liver enzyme elevation.
Seek medical advice if symptoms persist or become severe.
Globus Labs brings you WHO-GMP–certified, high-quality Febuxostat 80 mg sourced from reputed pharmaceutical manufacturers. Uxobus-80 is formulated to deliver safe, potent, and clinically trusted support.
Whether you’re seeking a franchise opportunity, exploring wholesale distribution, or evaluating Globus Labs for international trade, we’re here to help you build a strong, profitable partnership. Let’s discuss how we can grow together and create meaningful value for your business.